Loading
A phase 2 trial of Futibatinib, Pembrolizumab, Cisplatin and Oxaliplatin in oesophageal cancer and pancreatic ductal adenocarcinoma, run by Taiho Oncology, Inc., active and no longer recruiting.
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors is a phase 2 interventional study registered as NCT05945823 by Taiho Oncology, Inc., with 53 participants enrolled, started 2023-07-13 and due to reach its primary completion in 2026-10-01. Interventions recorded: Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin and Leucovorin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Araris Biotech (Taiho), Futibatinib, Cisplatin, Pembrolizumab and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Oxaliplatin, Oesophageal cancer, Pembrolizumab and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Oxaliplatin, Oesophageal cancer, Pembrolizumab and the tag pipeline.
Shares Araris Biotech (Taiho), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/